Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

• The dual-targeting approach effectively controls myeloma even with limited BCMA expression on tumor cells.
• Key evidence shows that bicistronic CAR T cells against BCMA and CD229 can target myeloma effectively despite lower BCMA levels.
• The method utilized involves examining BCMA and CD229 antigen expression on wild-type and BCMA knockout tumor cells.
• These findings suggest potential advancements in myeloma treatments, especially for cases with limited BCMA expression.